Jazz Pharmaceuticals plc — Director's Dealing 2021

May 7, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2021-05-05

Reporting Person: Tovey Christopher J. (EVP COO & Managing Dir EUR/INT)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	25	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$0.02	2031-02-22	Ordinary Shares (8063)		Direct

Footnotes

F1: Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger.